Tirzepatide
US$ 26.74
united therapeutics glp-1 receptor agonist agonists At the 2025 European Academy
Description
As use continues to grow, emergency physicians will encounter these medications more frequently across a broader patient population
Patient Selection & Clinical Decision-Making When orforglipron reaches the market, clinicians will face a new decision matrix: which GLP-1 therapy, among a growing array of options, best fits each individual patient
Ethics declarations Conflict of Interest The authors declare no competing interests
& Rodriguez, F
Frias JP, Deenadayalan S, Erichsen L, et al
10.1210/endocr/bqad153 50 MaoT.ZhangC.YangS.BiY.LiM.YuJ
